Exclusive Summary

• - US-registered sterile injectable with FDA-level quality enables reliance-based registrations and rapid market entry.
• - Targets acute musculoskeletal spasm needs in ED/perioperative settings across a global pool of 619M low back pain patients.
• - Fully generic with no patent barriers, enabling ~70–90% price reductions vs originator/legacy brands.
• - Standard 1 g/10 mL, room-temperature stable presentation simplifies hospital stocking and cross-border distribution.
• - Injectable coverage is thin in many regions; stable supply plus distribution partnerships can quickly fill channel gaps.